Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28399)	2/25/1999 10:43:00 AM
From: Hippieslayer	Respond to of 32384

oh so that's what the one and two are for???? But the point is Henry...at least one company has a drug that works.......in people!!!! :) Where are the rats????

To: Henry Niman who wrote (28399)	2/26/1999 4:31:00 AM
From: Cheryl Galt	Respond to of 32384

Henry, I read it. It looks like this CTRX news has implications for Type II also, though they're testing it first on Type I people. They claim it "substantially increases the body's sensitivity to insulin." (Incidentally, Metformin seems to do likewise.) This test was SMALL, a feasibility study -- with only 12 patients. A full-blown Phase II trial is now planned. Joslin and Harvard aren't fly-by-nights. Metabolic disease is complex. I'm glad (for personal reasons) for all the research and discovery diabetes can get. Considering the costs of diabetes, it gets a terribly small percentage of the total research dollars. The ADA has been campaigning to increase that. AS you've said, combo therapy will likely be the answer. Regards, Cheryl